Letrozole Tablets (Femara) is an oral aromatase inhibitor primarily used for the treatment of hormone receptor-positive early-stage or advanced breast cancer. As a highly effective endocrine therapy drug, it inhibits the synthesis of estrogen in the body, thereby suppressing tumor growth.

Indications of Letrozole Tablets (Femara)

Adjuvant Treatment for Early-Stage Breast Cancer

Letrozole Tablets are used as adjuvant therapy for patients with hormone receptor-positive early-stage breast cancer, aiming to reduce the risk of recurrence after surgery.

Clinical studies have shown that 5 years of letrozole treatment can significantly improve disease-free survival.

Extended Adjuvant Treatment for Early-Stage Breast Cancer

For patients who have completed 5 years of standard tamoxifen adjuvant therapy, Letrozole Tablets can be used as an extended adjuvant therapy drug to further reduce the risk of recurrence.

First-Line and Second-Line Treatment for Advanced Breast Cancer

Letrozole Tablets are indicated for patients with locally advanced or metastatic breast cancer that is hormone receptor-positive or has an unknown receptor status.

Whether used as initial treatment or as second-line treatment after the failure of anti-estrogen therapy (such as tamoxifen), letrozole has shown good efficacy and can effectively delay disease progression.

Specifications and Properties of Letrozole Tablets (Femara)

Specifications

Letrozole Tablets are an oral dosage form, with each tablet containing 2.5 mg of letrozole as the active ingredient.

The tablets are dark yellow, film-coated, round, slightly biconvex, with beveled edges.

One side of the tablet is imprinted with the letters "FV" and the other side with "CG" for easy identification.

Excipients

The tablets also contain a variety of excipients, including colloidal silicon dioxide, iron oxide, hypromellose, lactose monohydrate, magnesium stearate, maize starch, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate, talc, and titanium dioxide.

Properties

Letrozole itself is a white to pale yellow crystalline powder, almost odorless, freely soluble in dichloromethane, slightly soluble in ethanol, and practically insoluble in water.

Its chemical name is 4,4'-(1H-1,2,4-triazol-1-ylmethyl)dibenzonitrile, with a molecular weight of 285.31 g/mol.

Storage Methods for Letrozole Tablets (Femara)

Storage Conditions

Storage at 20°C to 25°C (68°F to 77°F) is recommended.

Short-term storage within the range of 15°C to 30°C (59°F to 86°F) is allowed, but frequent temperature fluctuations should still be avoided.

Packaging Form

Letrozole Tablets are usually packaged in high-density polyethylene (HDPE) bottles with child-resistant screw caps, containing 30 tablets per bottle.

Precautions

Keep the medication out of the reach of children.

Do not store the medication in humid places such as bathrooms or kitchens.

Expired or unused medication should be properly disposed of and must not be discarded randomly.